Disc Medicine (IRON) shares were down 2.4% in recent Thursday trading after the company posted a wider-than-expected loss in Q2.

The company earlier reported a Q2 loss of $1.58 per diluted share, wider than a loss of $1.03 a year earlier.

Analysts polled by FactSet expected a loss of $1.13.

As expected, no revenue was reported for the quarter ended June 30.

The company said that as of June 30, it had cash, cash equivalents, and marketable securities of $650 million, which are expected to fund its operational plans through 2028.

Price: 57.59, Change: -1.41, Percent Change: -2.39